Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of TRANS GENIC GROUP INC.. A complete text table follows the diagram.
Drug-discovery support is a meaningful second stream but much smaller than the investment and consulting business.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Nvestments & Consulting business | 1 | 5.3B | 85.0% of reported total |
| Drug discovery support business | 1 | 935M | 15.0% of reported total |
| Other & rounding | 1 | 0 | 0.0% of reported total |
| Revenues From External Customers | 2 | 6.2B | Reported six-month total · ¥6.2B |
| Operating profit | 3 | 71.4M | 1.1% operating margin |
| Operating costs & expenses | 3 | 6.2B | Arithmetic residual to reported operating profit |
| Profit before tax | 4 | 56.6M | Reported pretax result |
| TRANS GENIC is led by investments and consulting | 4 | 14.8M | Investments and consulting generated ¥5.290bn of external revenue versus ¥935m from drug-discovery support. |
| Net profit attributable to owners | 5 | 29.5M | Reported parent-company result |
| Tax, attribution & other | 5 | 27M | Arithmetic bridge to owners' profit |
| From | To | Value |
|---|---|---|
| Nvestments & Consulting business | Revenues From External Customers | 5.3B |
| Drug discovery support business | Revenues From External Customers | 935M |
| Other & rounding | Revenues From External Customers | 0 |
| Revenues From External Customers | Operating profit | 71.4M |
| Revenues From External Customers | Operating costs & expenses | 6.2B |
| Operating profit | Profit before tax | 56.6M |
| Operating profit | TRANS GENIC is led by investments and consulting | 14.8M |
| Profit before tax | Net profit attributable to owners | 29.5M |
| Profit before tax | Tax, attribution & other | 27M |